192 related articles for article (PubMed ID: 17276671)
1. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
[TBL] [Abstract][Full Text] [Related]
2. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
4. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
7. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
[TBL] [Abstract][Full Text] [Related]
9. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
11. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2003 Dec; 13(6):587-93. PubMed ID: 14646622
[TBL] [Abstract][Full Text] [Related]
13. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
[TBL] [Abstract][Full Text] [Related]
14. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
15. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
16. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
17. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
18. S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients.
Faye RS; Paus E; Maelandsmo GM; Berner A; Høifødt HK; Fodstad Ø; Aamdal S
Melanoma Res; 2008 Apr; 18(2):134-40. PubMed ID: 18337650
[TBL] [Abstract][Full Text] [Related]
19. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.
Krähn G; Kaskel P; Sander S; Waizenhöfer PJ; Wortmann S; Leiter U; Peter RU
Anticancer Res; 2001; 21(2B):1311-6. PubMed ID: 11396205
[TBL] [Abstract][Full Text] [Related]
20. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
